CPRX
Catalyst Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Market Cap: 1.87 Billion
Primary Exchange: NASDAQ
Website: https://catalystpharma.com/
Shares Outstanding: 118 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.2982394160599813
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 997 trading days
From: 2015-07-22 To: 2019-04-24
Lowest Point:
Catalyst sues FDA over approval of Firdapse competitor in LEMS
via: SeekingAlpha at 2019-06-12 05:22:46:000
Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome (LEM… read more...
Catalyst sues FDA over approval of Firdapse competitor in LEMS
via: SeekingAlpha at 2019-06-12 05:22:46:000
Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome (LEM… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|